File Download
 
Links for fulltext
(May Require Subscription)
 
Supplementary

Article: Elevated plasma adrenomedullin and vascular manifestations in patients with systemic sclerosis
  • Basic View
  • Metadata View
  • XML View
TitleElevated plasma adrenomedullin and vascular manifestations in patients with systemic sclerosis
 
AuthorsMok, MY1 2
Cheung, BMY1
Lo, Y1
Leung, RYH1
Wong, WS1 2
Lau, CS1
 
KeywordsChemicals And Cas Registry Numbers
 
Issue Date2007
 
PublisherJournal of Rheumatology Publishing Co Ltd. The Journal's web site is located at http://www.jrheum.com
 
CitationJournal Of Rheumatology, 2007, v. 34 n. 11, p. 2224-2229 [How to Cite?]
 
AbstractObjective. Adrenomedullin (ADM), a vasodilating peptide that possesses antiinflammatory properties, may have a regulatory role in the vascular manifestations of scleroderma (systemic sclerosis, SSc). We examined associapztions between ADM concentrations and vascular manifestations in a cohort of patients with SSc. Methods. Patients were examined for manifestations of severe Raynaud's phenomenon (RP), defined as digital resorption, previous iloprost infusion, and sympathectomy. Doppler echocardiography and lung function tests were performed to detect elevation in pulmonary arterial pressure (PAP; > 35 mm Hg) and interstitial lung disease (ILD). Plasma ADM was measured by radioimmunoassay. Results. Plasma ADM was measured in 62 SSc patients and 21 healthy controls. Elevated PAP was found in 15 (24.2%) SSc patients (mean PAP 46.5 ± 11.2 mm Hg, range 37-74). ADM was not found to be related to age, sex, disease duration, or clinical subset. ADM level was significantly higher (median 13.9 pmol/l) in SSc patients with elevated PAP compared to those with lower PAP (median 7.2 pmol/1) (p = 0.01) and controls (median 7.9 pmol/1) (p = 0.04). ADM level was not different among patients who had elevated PAP with (n = 10) and without concomitant ILD (n = 5) (p = 0.21). SSc patients with severe RP (38.7%; median ADM 11.9 pmol/1) were found not to have different ADM levels compared to controls (p = 0.75). Patients who had both severe RP and elevated PAP were found to have significantly higher ADM levels (median 22.3 pmol/l) than patients who had neither manifestation (median 8.0 pmol/1) (p = 0.006) and those with severe RP alone (median 4.2 pmol/1) (p = 0.006). Conclusion. Elevated ADM was found in SSc patients with increased PAP regardless of concomitant ILD.
 
ISSN0315-162X
2013 Impact Factor: 3.173
 
ISI Accession Number IDWOS:000250764000018
 
ReferencesReferences in Scopus
 
DC FieldValue
dc.contributor.authorMok, MY
 
dc.contributor.authorCheung, BMY
 
dc.contributor.authorLo, Y
 
dc.contributor.authorLeung, RYH
 
dc.contributor.authorWong, WS
 
dc.contributor.authorLau, CS
 
dc.date.accessioned2010-09-17T10:20:25Z
 
dc.date.available2010-09-17T10:20:25Z
 
dc.date.issued2007
 
dc.description.abstractObjective. Adrenomedullin (ADM), a vasodilating peptide that possesses antiinflammatory properties, may have a regulatory role in the vascular manifestations of scleroderma (systemic sclerosis, SSc). We examined associapztions between ADM concentrations and vascular manifestations in a cohort of patients with SSc. Methods. Patients were examined for manifestations of severe Raynaud's phenomenon (RP), defined as digital resorption, previous iloprost infusion, and sympathectomy. Doppler echocardiography and lung function tests were performed to detect elevation in pulmonary arterial pressure (PAP; > 35 mm Hg) and interstitial lung disease (ILD). Plasma ADM was measured by radioimmunoassay. Results. Plasma ADM was measured in 62 SSc patients and 21 healthy controls. Elevated PAP was found in 15 (24.2%) SSc patients (mean PAP 46.5 ± 11.2 mm Hg, range 37-74). ADM was not found to be related to age, sex, disease duration, or clinical subset. ADM level was significantly higher (median 13.9 pmol/l) in SSc patients with elevated PAP compared to those with lower PAP (median 7.2 pmol/1) (p = 0.01) and controls (median 7.9 pmol/1) (p = 0.04). ADM level was not different among patients who had elevated PAP with (n = 10) and without concomitant ILD (n = 5) (p = 0.21). SSc patients with severe RP (38.7%; median ADM 11.9 pmol/1) were found not to have different ADM levels compared to controls (p = 0.75). Patients who had both severe RP and elevated PAP were found to have significantly higher ADM levels (median 22.3 pmol/l) than patients who had neither manifestation (median 8.0 pmol/1) (p = 0.006) and those with severe RP alone (median 4.2 pmol/1) (p = 0.006). Conclusion. Elevated ADM was found in SSc patients with increased PAP regardless of concomitant ILD.
 
dc.description.natureLink_to_subscribed_fulltext
 
dc.identifier.citationJournal Of Rheumatology, 2007, v. 34 n. 11, p. 2224-2229 [How to Cite?]
 
dc.identifier.epage2229
 
dc.identifier.hkuros148448
 
dc.identifier.isiWOS:000250764000018
 
dc.identifier.issn0315-162X
2013 Impact Factor: 3.173
 
dc.identifier.issue11
 
dc.identifier.pmid17937467
 
dc.identifier.scopuseid_2-s2.0-35948991493
 
dc.identifier.spage2224
 
dc.identifier.urihttp://hdl.handle.net/10722/91501
 
dc.identifier.volume34
 
dc.languageeng
 
dc.publisherJournal of Rheumatology Publishing Co Ltd. The Journal's web site is located at http://www.jrheum.com
 
dc.publisher.placeCanada
 
dc.relation.ispartofJournal of Rheumatology
 
dc.relation.referencesReferences in Scopus
 
dc.subject.meshAdrenomedullin - blood
 
dc.subject.meshAdult
 
dc.subject.meshAged
 
dc.subject.meshAged, 80 and over
 
dc.subject.meshCase-Control Studies
 
dc.subject.meshFemale
 
dc.subject.meshHumans
 
dc.subject.meshHypertension, Pulmonary - blood - etiology
 
dc.subject.meshLung Diseases, Interstitial - blood - etiology
 
dc.subject.meshMale
 
dc.subject.meshMiddle Aged
 
dc.subject.meshRaynaud Disease - blood - etiology
 
dc.subject.meshScleroderma, Systemic - blood - complications - physiopathology
 
dc.subjectChemicals And Cas Registry Numbers
 
dc.titleElevated plasma adrenomedullin and vascular manifestations in patients with systemic sclerosis
 
dc.typeArticle
 
<?xml encoding="utf-8" version="1.0"?>
<item><contributor.author>Mok, MY</contributor.author>
<contributor.author>Cheung, BMY</contributor.author>
<contributor.author>Lo, Y</contributor.author>
<contributor.author>Leung, RYH</contributor.author>
<contributor.author>Wong, WS</contributor.author>
<contributor.author>Lau, CS</contributor.author>
<date.accessioned>2010-09-17T10:20:25Z</date.accessioned>
<date.available>2010-09-17T10:20:25Z</date.available>
<date.issued>2007</date.issued>
<identifier.citation>Journal Of Rheumatology, 2007, v. 34 n. 11, p. 2224-2229</identifier.citation>
<identifier.issn>0315-162X</identifier.issn>
<identifier.uri>http://hdl.handle.net/10722/91501</identifier.uri>
<description.abstract>Objective. Adrenomedullin (ADM), a vasodilating peptide that possesses antiinflammatory properties, may have a regulatory role in the vascular manifestations of scleroderma (systemic sclerosis, SSc). We examined associapztions between ADM concentrations and vascular manifestations in a cohort of patients with SSc. Methods. Patients were examined for manifestations of severe Raynaud&apos;s phenomenon (RP), defined as digital resorption, previous iloprost infusion, and sympathectomy. Doppler echocardiography and lung function tests were performed to detect elevation in pulmonary arterial pressure (PAP; &gt; 35 mm Hg) and interstitial lung disease (ILD). Plasma ADM was measured by radioimmunoassay. Results. Plasma ADM was measured in 62 SSc patients and 21 healthy controls. Elevated PAP was found in 15 (24.2%) SSc patients (mean PAP 46.5 &#177; 11.2 mm Hg, range 37-74). ADM was not found to be related to age, sex, disease duration, or clinical subset. ADM level was significantly higher (median 13.9 pmol/l) in SSc patients with elevated PAP compared to those with lower PAP (median 7.2 pmol/1) (p = 0.01) and controls (median 7.9 pmol/1) (p = 0.04). ADM level was not different among patients who had elevated PAP with (n = 10) and without concomitant ILD (n = 5) (p = 0.21). SSc patients with severe RP (38.7%; median ADM 11.9 pmol/1) were found not to have different ADM levels compared to controls (p = 0.75). Patients who had both severe RP and elevated PAP were found to have significantly higher ADM levels (median 22.3 pmol/l) than patients who had neither manifestation (median 8.0 pmol/1) (p = 0.006) and those with severe RP alone (median 4.2 pmol/1) (p = 0.006). Conclusion. Elevated ADM was found in SSc patients with increased PAP regardless of concomitant ILD.</description.abstract>
<language>eng</language>
<publisher>Journal of Rheumatology Publishing Co Ltd. The Journal&apos;s web site is located at http://www.jrheum.com</publisher>
<relation.ispartof>Journal of Rheumatology</relation.ispartof>
<subject>Chemicals And Cas Registry Numbers</subject>
<subject.mesh>Adrenomedullin - blood</subject.mesh>
<subject.mesh>Adult</subject.mesh>
<subject.mesh>Aged</subject.mesh>
<subject.mesh>Aged, 80 and over</subject.mesh>
<subject.mesh>Case-Control Studies</subject.mesh>
<subject.mesh>Female</subject.mesh>
<subject.mesh>Humans</subject.mesh>
<subject.mesh>Hypertension, Pulmonary - blood - etiology</subject.mesh>
<subject.mesh>Lung Diseases, Interstitial - blood - etiology</subject.mesh>
<subject.mesh>Male</subject.mesh>
<subject.mesh>Middle Aged</subject.mesh>
<subject.mesh>Raynaud Disease - blood - etiology</subject.mesh>
<subject.mesh>Scleroderma, Systemic - blood - complications - physiopathology</subject.mesh>
<title>Elevated plasma adrenomedullin and vascular manifestations in patients with systemic sclerosis</title>
<type>Article</type>
<description.nature>Link_to_subscribed_fulltext</description.nature>
<identifier.pmid>17937467</identifier.pmid>
<identifier.scopus>eid_2-s2.0-35948991493</identifier.scopus>
<identifier.hkuros>148448</identifier.hkuros>
<relation.references>http://www.scopus.com/mlt/select.url?eid=2-s2.0-35948991493&amp;selection=ref&amp;src=s&amp;origin=recordpage</relation.references>
<identifier.volume>34</identifier.volume>
<identifier.issue>11</identifier.issue>
<identifier.spage>2224</identifier.spage>
<identifier.epage>2229</identifier.epage>
<identifier.isi>WOS:000250764000018</identifier.isi>
<publisher.place>Canada</publisher.place>
</item>
Author Affiliations
  1. The University of Hong Kong
  2. Queen Mary Hospital Hong Kong